Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer. Panelists examine the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, ...

Simply sign up to the Private equity myFT Digest -- delivered directly to your inbox. Private equity group Warburg Pincus is nearing a deal to take a large minority stake in French diagnostics group ...

Acquisition strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre ® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade ...

Creditors are ready to provide debt financing in the amount of 3 billion euros as part of the proposed acquisition of the manufacturer of Zentiva generics. This is reported by foreign media. Earlier, ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

Exploring trends in Medicare utilization and reimbursement of germline genetic testing for cancer from 2017-2022. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This ...